171 related articles for article (PubMed ID: 25703736)
1. Characterization of patients with dystrophic epidermolysis bullosa for collagen VII therapy.
Gorell ES; Nguyen N; Siprashvili Z; Marinkovich MP; Lane AT
Br J Dermatol; 2015 Sep; 173(3):821-3. PubMed ID: 25703736
[No Abstract] [Full Text] [Related]
2. A Case of Dominant Dystrophic Epidermolysis Bullosa Responding Well to an Old Medication.
Leung J; Kuzel P; Kurian A; Brassard A
JAMA Dermatol; 2015 Nov; 151(11):1264-5. PubMed ID: 26154424
[No Abstract] [Full Text] [Related]
3. Mild recessive dystrophic epidermolysis bullosa associated with two compound heterozygous COL7A1 mutations.
von Bartenwerffer W; Has C; Arin MJ; Tantcheva-Poór I; Kreuter A; Kremer K; Arshah T; Hoffmann M; Eming SA; Kohlhase J; Krieg T; Bruckner-Tuderman L; Hartmann K
Eur J Dermatol; 2011; 21(2):170-2. PubMed ID: 21382783
[TBL] [Abstract][Full Text] [Related]
4. Immune reactivity to type VII collagen: implications for gene therapy of recessive dystrophic epidermolysis bullosa.
Pendaries V; Gasc G; Titeux M; Leroux C; Vitezica ZG; Mejía JE; Décha A; Loiseau P; Bodemer C; Prost-Squarcioni C; Hovnanian A
Gene Ther; 2010 Jul; 17(7):930-7. PubMed ID: 20376098
[TBL] [Abstract][Full Text] [Related]
5. Recessive dystrophic epidermolysis bullosa: the origin of the c.6527insC mutation in the Spanish population.
Sanchez-Jimeno C; Cuadrado-Corrales N; Aller E; García M; Escámez MJ; Illera N; Trujillo-Tiebas MJ; Ayuso C; Millán JM; Del Río M
Br J Dermatol; 2013 Jan; 168(1):226-9. PubMed ID: 22757647
[No Abstract] [Full Text] [Related]
6. Dominant Dystrophic Epidermolysis Bullosa Pruriginosa Responding to Naltrexone Treatment.
Pallesen KAU; Lindahl KH; Bygum A
Acta Derm Venereol; 2019 Nov; 99(12):1195-1196. PubMed ID: 31453628
[No Abstract] [Full Text] [Related]
7. Compound heterozygosity of the novel -186C>T mutation in the COL7A1 promoter and the recurrent c.497insA mutation leads to generalized dystrophic epidermolysis bullosa.
Ritelli M; Chiarelli N; Quinzani S; Dordoni C; Venturini M; Calzavara-Pinton P; Colombi M
Br J Dermatol; 2013 Apr; 168(4):904-6. PubMed ID: 23013315
[No Abstract] [Full Text] [Related]
8. Systemic protein therapy for recessive dystrophic epidermolysis bullosa: how far are we from clinical translation?
Hovnanian A
J Invest Dermatol; 2013 Jul; 133(7):1719-21. PubMed ID: 23760051
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for recessive dystrophic epidermolysis bullosa.
Titeux M; Pendaries V; Hovnanian A
Dermatol Clin; 2010 Apr; 28(2):361-6, xii. PubMed ID: 20447504
[TBL] [Abstract][Full Text] [Related]
10. Inversa dystrophic epidermolysis bullosa is caused by missense mutations at specific positions of the collagenic domain of collagen type VII.
Chiaverini C; Charlesworth AV; Youssef M; Cuny JF; Rabia SH; Lacour JP; Meneguzzi G
J Invest Dermatol; 2010 Oct; 130(10):2508-11. PubMed ID: 20555349
[No Abstract] [Full Text] [Related]
11. Recessive dystrophic epidermolysis bullosa: identification of a novel COL7A1 mutation of D44N.
Makino E; Nakano H; Sawamura D; Fujimoto W
J Dermatol Sci; 2012 Nov; 68(2):109-12. PubMed ID: 22854212
[No Abstract] [Full Text] [Related]
12. A Japanese family with dominant pretibial dystrophic epidermolysis bullosa: Identification of a new glycine substitution in the triple-helical collagenous domain of type VII collagen.
Hamada T; Fukuda S; Ishii N; Abe T; Nagata K; Koro O; Hatano Y; Nakano H; Sawamura D; Hashimoto T
J Dermatol Sci; 2009 Jun; 54(3):212-4. PubMed ID: 19269793
[No Abstract] [Full Text] [Related]
13. Dystrophic epidermolysis bullosa with one dominant and one recessive mutation of the COL7A1 gene in a child with deafness.
Weinel S; Lucky AW; Uitto J; Pfendner EG; Choo D
Pediatr Dermatol; 2008; 25(2):210-4. PubMed ID: 18429782
[TBL] [Abstract][Full Text] [Related]
14. Novel missense mutation of COL7A1 in a recessive dystrophic epidermolysis bullosa patient with mild clinical phenotype.
Yoshihara N; Nakano H; Sawamura D; Ikeda S
J Dermatol; 2014 Oct; 41(10):939-40. PubMed ID: 25227401
[No Abstract] [Full Text] [Related]
15. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa.
Woodley DT; Keene DR; Atha T; Huang Y; Lipman K; Li W; Chen M
Nat Med; 2004 Jul; 10(7):693-5. PubMed ID: 15195089
[TBL] [Abstract][Full Text] [Related]
16. A COL7A1 variant leading to in-frame skipping of exon 15 attenuates disease severity in recessive dystrophic epidermolysis bullosa.
Schwieger-Briel A; Weibel L; Chmel N; Leppert J; Kernland-Lang K; Grüninger G; Has C
Br J Dermatol; 2015 Nov; 173(5):1308-11. PubMed ID: 26076072
[No Abstract] [Full Text] [Related]
17. siRNA-mediated allele-specific inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa.
Pendaries V; Gasc G; Titeux M; Tonasso L; Mejía JE; Hovnanian A
J Invest Dermatol; 2012 Jun; 132(6):1741-3. PubMed ID: 22336946
[No Abstract] [Full Text] [Related]
18. X-linked ichthyosis along with recessive dystrophic epidermolysis bullosa in the same patient.
Hernández-Martín A; Cuadrado-Corrales N; Ciria-Abad S; Arias-Palomo D; Mascaró-Galy JM; Escámez MJ; García M; Del Río M; Torrelo A; González-Sarmiento R
Dermatology; 2010; 221(2):113-6. PubMed ID: 20523032
[TBL] [Abstract][Full Text] [Related]
19. Novel deletion mutation (c.3717del5) in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa.
Lee SH; Kim SE; Noh EB; Oh SW; Kim SC
J Dermatol; 2013 Jan; 40(1):59-61. PubMed ID: 22974128
[No Abstract] [Full Text] [Related]
20. A mutation-independent therapeutic strategy for dominant dystrophic epidermolysis bullosa.
Morgan CP; Allen DSI; Millington-Ward S; O'Dwyer GE; Palfi A; Jane Farrar G
J Invest Dermatol; 2013 Dec; 133(12):2793-2796. PubMed ID: 23743647
[No Abstract] [Full Text] [Related]
[Next] [New Search]
